Maternal Genome-Wide DNA Methylation Patterns and Congenital Heart Defects

The majority of congenital heart defects (CHDs) are thought to result from the interaction between multiple genetic, epigenetic, environmental, and lifestyle factors. Epigenetic mechanisms are attractive targets in the study of complex diseases because they may be altered by environmental factors and dietary interventions. We conducted a population based, case-control study of genome-wide maternal DNA methylation to determine if alterations in gene-specific methylation were associated with CHDs. Using the Illumina Infinium Human Methylation27 BeadChip, we assessed maternal gene-specific methylation in over 27,000 CpG sites from DNA isolated from peripheral blood lymphocytes. Our study sample included 180 mothers with non-syndromic CHD-affected pregnancies (cases) and 187 mothers with unaffected pregnancies (controls). Using a multi-factorial statistical model, we observed differential methylation between cases and controls at multiple CpG sites, although no CpG site reached the most stringent level of genome-wide statistical significance. The majority of differentially methylated CpG sites were hypermethylated in cases and located within CpG islands. Gene Set Enrichment Analysis (GSEA) revealed that the genes of interest were enriched in multiple biological processes involved in fetal development. Associations with canonical pathways previously shown to be involved in fetal organogenesis were also observed. We present preliminary evidence that alterations in maternal DNA methylation may be associated with CHDs. Our results suggest that further studies involving maternal epigenetic patterns and CHDs are warranted. Multiple candidate processes and pathways for future study have been identified

Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark

Background: Hypothesised associations between in utero exposure to selective serotonin reuptake inhibitors (SSRIs) and congenital anomalies, particularly congenital heart defects (CHD), remain controversial. We investigated the putative teratogenicity of SSRI prescription in the 91 days either side of first day of last menstrual period (LMP). Methods and Findings: Three population-based EUROCAT congenital anomaly registries- Norway (2004–2010), Wales (2000–2010) and Funen, Denmark (2000–2010)—were linked to the electronic healthcare databases holding prospectively collected prescription information for all pregnancies in the timeframes available. We included 519,117 deliveries, including foetuses terminated for congenital anomalies, with data covering pregnancy and the preceding quarter, including 462,641 with data covering pregnancy and one year either side. For SSRI exposures 91 days either side of LMP, separately and together, odds ratios with 95% confidence intervals (ORs, 95%CI) for all major anomalies were estimated. We also explored: pausing or discontinuing SSRIs preconception, confounding, high dose regimens, and, in Wales, diagnosis of depression. Results were combined in meta-analyses. SSRI prescription 91 days either side of LMP was associated with increased prevalence of severe congenital heart defects (CHD) (as defined by EUROCAT guide 1.3, 2005) (34/12,962 [0.26%] vs. 865/506,155 [0.17%] OR 1.50, 1.06–2.11), and the composite adverse outcome of 'anomaly or stillbirth' (473/12962, 3.65% vs. 15829/506,155, 3.13%, OR 1.13, 1.03–1.24). The increased prevalence of all major anomalies combined did not reach statistical significance (3.09% [400/12,962] vs. 2.67% [13,536/506,155] OR 1.09, 0.99–1.21). Adjusting for socio-economic status left ORs largely unchanged. The prevalence of anomalies and severe CHD was reduced when SSRI prescriptions were stopped or paused preconception, and increased when >1 prescription was recorded, but differences were not statistically significant. The dose-response relationship between severe CHD and SSRI dose (meta-regression OR 1.49, 1.12–1.97) was consistent with SSRI-exposure related risk. Analyses in Wales suggested no associations between anomalies and diagnosed depression. Conclusion: The additional absolute risk of teratogenesis associated with SSRIs, if causal, is small. However, the high prevalence of SSRI use augments its public health importance, justifying modifications to preconception care

Tetranuclear iron(III) complexes of an octadentate pyridine-carboxylate ligand and their catalytic activity in alkane oxidation by hydrogen peroxide

Reaction of the octadentate ligand 2,6-bis{3-[N,N-di(2-pyridylmethyl)amino]propoxy}benzoic acid (LH) with Fe(ClO4)(3) leads to the formation of the tetranuclear complexes [Fe-4(mu-O)(2)(LH)(2)(ClCH2 CO2)(4)](ClO4)(4) (1), [{Fe-2(mu-O)L(R-CO2)}(2)](ClO4)(4) (2 R = C6H5-, 3 R = CH3-, 4, R = ClCH2-). The crystal structures of complexes 1 and 2 reveal that they consist of two Fe-2(III)(mu-O)(mu-RCO2)(2) cores that are linked via the two LH/L ligands to give a "dimer of dimers" structure. Complex I assumes a helical shape, with protonated carboxylic acid moieties of the two ligands forming a hydrogen-bonded pair at the center of the cation. In complexes 2, 3 and 4, central carboxylates of the two ligands bridge the iron ions in each of the two Fe, O units, with an interdimer iron-iron separation of approximately 10 angstrom and an intradimer separation of approximately 3.1 angstrom. The second carboxylate bridge within the Fe2O units is defined by exogenous benzoate (2), acetate (3) or chloroacetate (4) ligands. The aqua complex [{Fe-2(mu-O)L(H2O)(2)}(2)](ClO4)(6) (5) is proposed to have a similar structure, but with the exogenous bridging carboxylates replaced by two terminal water ligands. These complexes exhibit electronic and Mossbauer spectral features that are similar to those of (mu-oxo)diiron(iii) proteins as well as other related (mu-oxo)bis(mu-carboxylato)diiron(III) complexes. This similarity shows that these properties are not significantly affected by the nature of the bridging exogenous carboxylate, and that the octadentate framework ligand is essential in stabilizing the "dimer of dimers" structure. This structural feature remains in highly diluted solution (10(-5) M) as evidenced by electrospray ionization mass-spectroscopy (ES MS). Cyclic voltammetric studies of complexes 2 and 5 showed two irreversible two-electron reductions, indicating that the two Fe2O units of the tetranuclear complexes behave as distinct redox entities. Complexes 2, 3 and, especially, the aqua complex 5 are active alkane oxidation catalysts. Catalytic reactions carried out with alkane substrate molecules and hydrogen peroxide predominantly gave alcohols. High stereospecificity in the oxidation of cis- 1,2-dimethylcyclohexane supports the metal-based molecular mechanism of O-insertion into C-H bonds postulated for non-heme iron enzymes such as methane monooxygenase